| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Welch Daniel G |
Director |
– • – |
2023-03-15 |
4 |
AS |
$200.05 |
$249,262 |
I/I |
(1,246) |
23,060 |
|
-3% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-15 |
4 |
AS |
$200.05 |
$471,518 |
D/D |
(2,357) |
6,899 |
|
-3% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-15 |
4 |
OE |
$38.82 |
$79,076 |
D/D |
2,037 |
9,256 |
|
- |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-03-15 |
4 |
AS |
$199.81 |
$1,998,115 |
D/D |
(10,000) |
96,853 |
|
-3% |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-03-15 |
4 |
OE |
$72.64 |
$726,400 |
D/D |
10,000 |
106,853 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2023-03-14 |
4 |
AS |
$200.00 |
$57,600 |
I/I |
(288) |
24,306 |
|
-2% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-14 |
4 |
AS |
$200.00 |
$108,800 |
D/D |
(544) |
12,977 |
|
-2% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-14 |
4 |
OE |
$38.82 |
$18,245 |
D/D |
470 |
13,447 |
|
- |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,660 |
98,513 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2023-03-13 |
4 |
AS |
$200.20 |
$1,841,487 |
I/I |
(9,191) |
24,594 |
|
-2% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-13 |
4 |
AS |
$200.06 |
$3,481,015 |
D/D |
(17,374) |
7,219 |
|
-2% |
|
| Welch Daniel G |
Director |
– • – |
2023-03-13 |
4 |
OE |
$38.82 |
$593,370 |
D/D |
15,018 |
23,036 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-03-09 |
4 |
AS |
$175.89 |
$7,557,550 |
D/D |
(42,793) |
117,185 |
|
13% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-03-09 |
4 |
OE |
$45.30 |
$1,938,523 |
D/D |
42,793 |
159,978 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-03-02 |
4 |
AS |
$177.07 |
$2,873,477 |
D/D |
(16,215) |
67,257 |
|
10% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2023-03-02 |
4 |
OE |
$41.04 |
$665,464 |
D/D |
16,215 |
69,948 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-02-27 |
4 |
AS |
$182.53 |
$3,650,600 |
D/D |
(20,000) |
117,185 |
|
7% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
AS |
$160.00 |
$6,391,400 |
D/D |
(39,946) |
137,185 |
|
20% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
OE |
$39.15 |
$1,563,886 |
D/D |
39,946 |
177,131 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-02-16 |
4 |
AS |
$155.00 |
$775,000 |
D/D |
(5,000) |
85,113 |
|
20% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-02-16 |
4 |
OE |
$39.15 |
$195,750 |
D/D |
5,000 |
90,113 |
|
- |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-02-15 |
4 |
AS |
$138.62 |
$1,406,395 |
D/D |
(10,000) |
96,853 |
|
38% |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-02-15 |
4 |
OE |
$72.64 |
$726,400 |
D/D |
10,000 |
106,853 |
|
- |
|
| Gryska David W |
Director |
– • – |
2023-02-13 |
4 |
OE |
$36.70 |
$321,125 |
D/D |
8,750 |
49,003 |
|
- |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-02-02 |
4 |
AS |
$138.52 |
$108,461 |
D/D |
(783) |
96,853 |
|
41% |
|
1805 Records found
|
|
Page 5 of 73 |
|
|
